Case Reports of Hematological Diseases

Dear Colleagues, 

Hematology is undergoing rapid transformation driven by advances in molecular diagnostics, genomic profiling, precision medicine, targeted therapies, immunotherapy, cellular therapy, and hematopoietic stem cell transplantation. Despite these developments, individual patients frequently present with unusual clinical manifestations, unexpected laboratory or pathological findings, atypical disease courses, rare complications, or responses to treatment that are not adequately represented in large clinical studies. Carefully documented case reports and case series therefore remain important sources of clinical knowledge, particularly when they identify new disease presentations, expose diagnostic pitfalls, describe uncommon treatment responses or toxicities, or generate hypotheses for future investigation. 

The increasing integration of morphology, flow cytometry, cytogenetics, molecular genetics, imaging, and advanced laboratory technologies has also changed the diagnostic landscape of both malignant and non-malignant hematological disorders. At the same time, novel targeted agents, immune-based therapies, and cellular treatments have created new therapeutic opportunities accompanied by previously unrecognized complications and management challenges. Sharing high-quality clinical observations can consequently improve disease recognition, clinical decision-making, and patient management. 

This Special Issue aims to present and disseminate clinically meaningful case reports and case series across the spectrum of hematological diseases, with particular emphasis on cases that provide novel diagnostic, pathological, molecular, therapeutic, or prognostic insights. We particularly encourage submissions that clearly describe the clinical reasoning involved, integrate relevant laboratory and pathological findings, and identify lessons that may influence clinical practice or stimulate further research. Topics of interest for publication include, but are not limited to, the following: 

• Rare or atypical presentations of leukemia and lymphoma;
• Myelodysplastic syndromes and myeloproliferative neoplasms;
• Plasma cell disorders and other hematological malignancies;
• Rare anemias, hemoglobinopathies, and red blood cell disorders;
• Bone marrow failure syndromes and unexplained cytopenias;
• Platelet, coagulation, thrombotic, and bleeding disorders;
• Diagnostic challenges involving morphology, flow cytometry, cytogenetics, and molecular testing;
• Germline predisposition to hematological malignancies and hereditary hematological disorders;
• Unusual molecular or genomic findings with clinical relevance;
• Precision medicine and biomarker-guided therapeutic decisions;
• Novel targeted therapies, immunotherapies, and cellular therapies;
• CAR-T-cell therapy and other emerging hematological treatments;
• Hematopoietic stem cell transplantation and associated complications;
• Unexpected treatment responses, resistance, adverse events, and drug-related hematological complications;
• Infectious, immune, and inflammatory complications in patients with hematological diseases;
• Hematological manifestations of systemic diseases, infections, and malignancies;
• Pediatric, adolescent, adult, and geriatric hematology cases;
• Cases highlighting important multidisciplinary or transfusion-medicine considerations.

We welcome well-documented reports that go beyond rarity alone and provide a clear clinical message, mechanistic insight, diagnostic lesson, or therapeutic implication capable of advancing understanding and improving the management of hematological diseases. 

Dr. Saeed Kabrah
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.